Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.

Ebi H, Costa C, Faber AC, Nishtala M, Kotani H, Juric D, Della Pelle P, Song Y, Yano S, Mino-Kenudson M, Benes CH, Engelman JA.

Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21124-9. doi: 10.1073/pnas.1314124110. Epub 2013 Dec 10.

2.

P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.

Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW.

Oncogene. 2015 Jul 23;34(30):3968-76. doi: 10.1038/onc.2014.328. Epub 2014 Oct 6.

3.

Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.

Tanizaki J, Okamoto I, Fumita S, Okamoto W, Nishio K, Nakagawa K.

Oncogene. 2011 Sep 29;30(39):4097-106. doi: 10.1038/onc.2011.111. Epub 2011 Apr 18.

PMID:
21499301
4.

PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.

Aksamitiene E, Kholodenko BN, Kolch W, Hoek JB, Kiyatkin A.

Cell Signal. 2010 Sep;22(9):1369-78. doi: 10.1016/j.cellsig.2010.05.006. Epub 2010 May 12.

5.

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.

Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, Lifshits E, Chen Z, Maira SM, García-Echeverría C, Wong KK, Engelman JA.

Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19503-8. doi: 10.1073/pnas.0905056106. Epub 2009 Oct 22.

6.

Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.

Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

Clin Cancer Res. 2012 Jan 15;18(2):380-91. doi: 10.1158/1078-0432.CCR-11-2035. Epub 2011 Nov 16.

7.

Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.

Rexer BN, Chanthaphaychith S, Dahlman K, Arteaga CL.

Breast Cancer Res. 2014 Jan 23;16(1):R9. doi: 10.1186/bcr3601.

8.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

PMID:
16854453
9.

The Phosphatidylinositol (3,4,5)-Trisphosphate-dependent Rac Exchanger 1·Ras-related C3 Botulinum Toxin Substrate 1 (P-Rex1·Rac1) Complex Reveals the Basis of Rac1 Activation in Breast Cancer Cells.

Lucato CM, Halls ML, Ooms LM, Liu HJ, Mitchell CA, Whisstock JC, Ellisdon AM.

J Biol Chem. 2015 Aug 21;290(34):20827-40. doi: 10.1074/jbc.M115.660456. Epub 2015 Jun 24.

10.

Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.

Yuen HF, Abramczyk O, Montgomery G, Chan KK, Huang YH, Sasazuki T, Shirasawa S, Gopesh S, Chan KW, Fennell D, Janne P, El-Tanani M, Murray JT.

Biosci Rep. 2012 Aug;32(4):413-22. doi: 10.1042/BSR20120050.

11.

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.

Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Wong KK, Cantley LC, Engelman JA.

J Clin Invest. 2011 Nov;121(11):4311-21. doi: 10.1172/JCI57909. Epub 2011 Oct 10.

12.

HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.

Kirouac DC, Du J, Lahdenranta J, Onsum MD, Nielsen UB, Schoeberl B, McDonagh CF.

PLoS Comput Biol. 2016 Apr 1;12(4):e1004827. doi: 10.1371/journal.pcbi.1004827. eCollection 2016 Apr.

13.
15.

PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.

Wu CY, Carpenter ES, Takeuchi KK, Halbrook CJ, Peverley LV, Bien H, Hall JC, DelGiorno KE, Pal D, Song Y, Shi C, Lin RZ, Crawford HC.

Gastroenterology. 2014 Dec;147(6):1405-16.e7. doi: 10.1053/j.gastro.2014.08.032. Epub 2014 Aug 27.

16.

Characterization of P-Rex1 for its role in fMet-Leu-Phe-induced superoxide production in reconstituted COS(phox) cells.

Nie B, Cheng N, Dinauer MC, Ye RD.

Cell Signal. 2010 May;22(5):770-82. doi: 10.1016/j.cellsig.2010.01.001. Epub 2010 Jan 13.

17.

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA.

Biochim Biophys Acta. 2007 Aug;1773(8):1263-84. Epub 2006 Oct 7. Review.

18.

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F.

Cancer Res. 2009 May 15;69(10):4286-93. doi: 10.1158/0008-5472.CAN-08-4765. Epub 2009 Apr 28.

19.

[Overexpression of HER2/neu downregulates wild p53 protein expression via PI3K and Ras/Raf/MEK/ERK pathways in human breast cancer cells].

Zheng L, Ren JQ, Zhang L, Chen Q, Zhu HG.

Zhonghua Bing Li Xue Za Zhi. 2004 Aug;33(4):358-62. Chinese.

PMID:
15363324
20.

Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.

Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, Huang X, Monian P, Jiang X, de Stanchina E, Baselga J, Liu N, Chandarlapaty S, Rosen N.

Cancer Discov. 2014 Mar;4(3):334-47. doi: 10.1158/2159-8290.CD-13-0611. Epub 2014 Jan 16.

Items per page

Supplemental Content

Write to the Help Desk